Top High Tech Stocks To Buy For 2015

Top High Tech Stocks To Buy For 2015: Vanda Pharmaceuticals I nc.(VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is also developing Tasimelteon, an orphan medicinal product for the treatment of sleep and mood disorders, including non-24 hour sleep/wake disorder in blind individuals without light perception. It also intends to initiate a Phase IIb/III clinical trial of tasimelteon in patients with major depressive disorder; and conduct additional clinical trials to support the use of tasimelteon as a circadian regulator. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.

Advisors' Opinion:

• [By Nathalie Tadena]

  Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).

• [By John Udovich]

  Small cap biopharmaceutical stockVanda Pharmaceuticals Inc (NASDAQ: VNDA) surged 14.02% after announcing a settlement agreement with Novartis AG (NYSE: NVS) related to ongoing license arbitration proceedings for Fanapt, a schizophrenia treatment drug meaning its worth taking a closer look at the stock along with large caps Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb Co (NYSE: BMY) which also have important schizophrenia drugs in their portfolios.

• [By MONEYMORNING.COM]

  The FDA Peripheral and Central Nervous System Drugs Advisory Committee (AdCom) met last November to review Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA) New Drug Application (NDA) for tasimelteon, an experimental drug for the treatment of a serious condition among blind people that radically affects their sleeping patterns: non-24-hour disorder. The panel voted overwhelmingly in f! avor of tasimelteon. Vanda's stock share price rocketed upward 115%.
  
  In January 2014, FDA's Cardiovascular and Renal Drugs Advisory Committee voted 16 to 1 in favor of approval for Chelsea Therapeutics International Ltd.'s (Nasdaq: CHTP) pipeline drug Northera (droxidopa), designed to prevent dizziness and fainting among patients with neurodegenerative diseases. Chelsea's share price immediately soared 150%.

• [By Paul Ausick]

  Stocks on the Move: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is up 95.8% at $13.29 on FDA recommendation for approval of its sleep drug for the blind. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is down 64.3% at $13.05 following an FDA rejection of the companys bid to fast-track muscular dystrophy drug. U.S. Airways Group Inc. (NYSE: LCC) is up 1.1% at $23.53 after reaching an agreement with the Department of Justice that will let the company go ahead with its American Airlines merger.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-high-tech-stocks-to-buy-for-2015-4.html